M&A activity is reshaping the healthcare industry with record-setting deals like CVS-Aetna and Cigna-Express Scripts’ vertical mergers spurring new paths for the next big deal. One key driver of healthcare M&A is the growing adoption of technology in patient care and diagnostics like AI (expected to be an almost $200 billion industry by 2025), VR, 3D printing, nano medicine and robotics. This has led to a growing need for synergies and consolidation within the industry to address changing reimbursement models, the need to increase access to care and to improve the quality of healthcare.
Buyers, Sellers and Facilitators: An M&A Discussion
S&C healthcare M&A partner Keith Pagnani will be moderating a “CEOs Unplugged” panel discussion at this year’s MedTech Conference titled “Buyers, Sellers and Facilitators: An M&A Discussion.”
The panel will focus on the impact of some of the recent M&A deals in healthcare and discuss trends in valuation, deal structure and other interesting deal aspects. Keith will be joined by panelists Carin Fradin, Managing Director of JMP Securities, and Dev Kurdikar, Former President and CEO at Cardiac Science.
Keith recently appeared on Nasdaq and Director Corp’s Looking Ahead: Trends in Corporate Leadership video series.
About Keith Pagnani
Keith Pagnani is co-head of S&C’s Healthcare & Life Sciences Group and was recently named a “2019 Health Care Law Trailblazer” by the National Law Journal. He has also been recognized by The American Lawyer as “Dealmaker of the Week” and “Dealmaker of the Year.”
Keith is actively involved in Sullivan & Cromwell’s corporate practice and has broad experience representing buyers, sellers, special committees of independent directors and financial advisers on a wide range of domestic and international merger and acquisition transactions.
Learn more about Keith’s practice
Sullivan & Cromwell’s Healthcare M&A Group
Healthcare accounts for more than $915 billion in announced M&A matters worldwide since January 2018. S&C’s Healthcare & Life Sciences Group has been at the forefront of this healthcare M&A activity, bringing its creativity, culture of collaboration and deal prowess to advise an assortment of clients across the healthcare industry on some of the biggest and most significant matters.
Since 2014, the Group has advised on nearly $650 billion in announced healthcare M&A transactions worldwide, including many multi-billion-dollar transformative, cross-border
matters.